Compugen Ltd. Discloses Splice Variant Based Program to Discover Superior Oncology Drug Targets for mAb Therapy

TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) announced today that it is utilizing its proprietary in silico human transcriptome and proteome and additional computational systems to discover splice variants of known drug targets of high industry interest and of other known proteins with potential to become cancer targets for mAb therapy. This program has resulted so far in the discovery of four novel splice variant proteins predicted to be superior oncology targets compared with the previously known proteins. These four splice variants have entered Compugen’s Pipeline Program and are at various stages of validation.